Geneva, Jun 8: The Democratic Republic of the Congo (DRC) has approved the use of five investigational therapeutics to treat Ebola virus disease (EVD), the World Health Organization (WHO) has said.
Four of the five approved drugs are currently in the country, which are Zmapp, GS-5734, REGN monoclonal antibody combination, and mAb114, under the framework of compassionate use and expanded access, China’s official new agency Xinhua quoted the WHO as saying.
Clinicians working in the treatment centers will make decisions on which drug to use as deemed helpful for their patients, and appropriate for the setting. The treatments can be used as long as informed consent is obtained from patients and protocols are followed, with close monitoring and reporting of any adverse events.
